干扰素抗体与HBV C基因启动子变异对干扰素疗效的影响  

The effect of anti-interferon antibody on therapeutic efficacy of interferon in chronic hepatitis B with core promoter mutation.

作　　者：邢利和[1] 王福生[1] 朱传琳[2] 李力 王慧芬[2] 雷周云[1] 

机构地区：[1]北京解放军第三0二医院传染病研究所生物工程研究室,100039 [2]北京解放军第三0二医院四科,100039

出　　处：《肝脏》2001年第4期228-230,共3页Chinese Hepatology

摘　　要：目的　探讨HBVC基因启动子 (BCP)变异的肝炎患者干扰素抗体 (抗 IFN )的产生对干扰素疗效的影响。方法　采用错配PCR RFLP技术检测 89例慢性乙型肝炎血清中BCP变异和血清中抗 IFN的水平。结果　BCP变异率为 5 2 .8%,抗 IFN阳性率为 15 .6 %,而干扰素治疗前抗 IFN阳性与治疗后转为阳性的患者 ,其干扰素治疗的有效率差异无显著性 (P >0 .0 5 ) ,而治疗前后抗 IFN均为阴性者 ,其有效率明显优于阳性者 ,差异显著 (P <0 .0 5 )。在IFN治疗前 ,有BCP变异组抗 IFN阳性 10例 ,野生株组抗 IFN阳性 2例 ,两组相比 ,差异显著 (P <0 .0 5 )。IFN治疗后 ,变异株组出现抗 IFN阳性 4例 ,野生株组出现抗 IFN阳性 1例 ,差异无显著性 (P >0 .0 5 )。结论　抗 IFN阳性的患者 ,干扰素治疗效果差。BCP变异的患者 ,在干扰素治疗前 ,有可能促进干扰素抗体的产生 ,但在干扰素治疗后 ,则不增加抗 IFN的产生。Objective To investigate the effect of anti-interferon antibody on interferon efficacy in the treatment of chronic hepatitis B patients with HBV core promoter mutation. Methods The core promoter gene mutants with chronic hepatitis B were detected by using mismatch-PCR restriction fragment length polymorphism assay and the levels of serum anti-interferon antibody with interferon treatment was also observed in this study.Results The efficacy rates of interferon treatmnet has not statistical significance (P>0.05) in the anti-IFN antibody positive patients after and before interferon treatment, but it has a significant difference in anti-IFN antibody negative patients after and before treatment than that of in anti-IFN antibody positive patients(P<0.05). Before interferon treatment, there were 10 cases of anti-IFN positive in core promoter mutation group, it has a significant difference than that in wild-type group with only 2 cases of anti-IFN positive (P<0.05). After interferon treatment, there was no significant difference between the mutant-type group with 4 cases anti-IFN positive and the wild-type group with 1 cases anti-IFN positive (P>0.05). Conclusion The treatmnet efficacy of interferon was reduced in those anti-IFN antibody positive patients. It is probably for the core promoter mutation patients due to increase the production of anti-IFN antibody levels before interferon treatment, but no increase of the levels of anti-IFN after interferon treatment.

关 键 词：乙型肝炎病毒 C基因启动子 变异 干扰素抗体 干扰素 HBV 

分 类 号：R512.6[医药卫生—内科学]